echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Cardiovasc Diabetol: Sodium-sugar cotransporter inhibitor can significantly reduce the risk of cardiovascular events in patients with T2DM

    Cardiovasc Diabetol: Sodium-sugar cotransporter inhibitor can significantly reduce the risk of cardiovascular events in patients with T2DM

    • Last Update: 2021-07-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    About Type 2 diabetes mellitus (T2DM) patients prospectively heart blood vessels results (CV) outcome trials support the use of sodium - glucose cotransporter 2 inhibitor (SGLT2i) T2DM patients to reduce cardiovascular event risk
    .

    Diabetes, heart blood vessel using sodium - glucose cotransporter 2 inhibitor (SGLT2i) T2DM patients to reduce cardiovascular event risk for cardiovascular events

    The CVD-REAL Catalonia trial is a retrospective cohort study that uses real-world data collected daily from 2013 to 2016 to compare SGLT2i and other new users of hypoglycemic drugs (oGLD).
    The risk of vascular events
    .

    According to the propensity score, new users of matched SGLT2i and oGLD were included in a ratio of 1:1
    .
    The incidence and risk ratio (HR) of all-cause mortality, heart failure hospitalization, chronic kidney disease, and adjusted major adverse CV events (MACE; all-cause mortality, myocardial infarction or stroke ) were compared


    .


    Heart failure myocardial infarction stroke

    The occurrence of various outcomes of the two groups of subjects

    The occurrence of various outcomes of the two groups of subjects

    After matching the propensity scores, each group included 12,917 new users
    .
    About 27% of the subjects had a history of cardiovascular disease


    .


    Each group included 12,917 new users with SGLT2i use and lower heart failure (HR 0.


    Original source:

    Original source:

    Real, J.


    Cardiovascular and mortality benefits of sodium--glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.